1.80
+0.03(+1.69%)
Currency In USD
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
19
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Mr. Guido Baechler | Chief Executive Officer & Executive Director | 0 | 1965 |
| Mr. Stefan Erlach | Head of Human Resources | 0 | N/A |
| Dr. Frank Krieg-Schneider | Chief Technology Officer | 0 | 1962 |
| Dr. Christopher Von Toerne P.M.P., Ph.D. | Chief Operating Officer | 0 | 1972 |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director | 0 | 1984 |
| Mr. Philipp Freese | Chief Business Officer | 0 | 1983 |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.